• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Veraxa Biotech AG - Ordinary Shares (NQ:VRXA)

    1.874 +0.054 (+2.95%)
    Streaming Delayed Price Updated: 10:02 AM EDT, Aug 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Veraxa Biotech AG - Ordinary Shares

    < Previous 1 2 Next >
    VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies
    Via Investor Brand Network
    Topics Intellectual Property
    VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform
    Via Investor Brand Network
    InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
    First BiTAC®-related patent applications filed in H1 2026 including patents covering composition of matter and proprietary payload platform, with additional patents secured in contributing technology... 
    From Veraxa Biotech AG
    Via GlobeNewswire
    MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures
    Via Investor Brand Network
    BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
    Via Investor Brand Network
    News headline image
    VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
    VXA-222 advances into next phase at VERAXA 
    From Veraxa Biotech AG
    Via GlobeNewswire
    News headline image
    VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
    From Veraxa Biotech AG
    Via GlobeNewswire
    NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer
    Via Investor Brand Network
    News headline image
    VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
    From Veraxa Biotech AG
    Via GlobeNewswire
    VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany
    Via Investor Brand Network
    MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
    Via Investor Brand Network
    News headline image
    VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
    Scientific Advice from the German Regulatory Authority supports the biological rationale and proposed development approach for VERAXA's BiTAC-TCE technology and product candidate, providing an initial... 
    From Veraxa Biotech AG
    Via GlobeNewswire
    Why VERAXA Biotech AG (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D
    Via Investor Brand Network
    Topics Artificial Intelligence
    InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development
    Via Investor Brand Network
    Topics Artificial Intelligence
    NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Carl von Halem Interim Chief Financial Officer
    Via Investor Brand Network
    News headline image
    VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
    Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) 
    From Veraxa Biotech AG
    Via GlobeNewswire
    News headline image
    VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
    From VERAXA Biotech GmbH
    Via GlobeNewswire
    VERAXA Biotech AG (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership
    Via Investor Brand Network
    MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition
    Via Investor Brand Network
    BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
    Via Investor Brand Network
    BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
    Via Investor Brand Network
    News headline image
    VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
    Novel conditionally active T cell engagers sourced from proprietary BiTAC® platform are at the basis of advanced partnering initiatives and development activities 
    From VERAXA Biotech GmbH
    Via GlobeNewswire
    BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
    Via Investor Brand Network
    News headline image
    VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
    ATUM, a leading US-based contract research organization, selected to support stable clonal cell line generation to advance VERAXA’s lead BiTAC-TCE program toward IND/CTA-enabling activities 
    From VERAXA Biotech GmbH
    Via GlobeNewswire
    Why VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals
    Via Investor Brand Network
    InvestorNewsBreaks – Xlife Sciences AG (SIX: XLS) Shareholders Approve All Annual Meeting Proposals
    Via Investor Brand Network
    VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline
    Via Investor Brand Network
    BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline
    Via Investor Brand Network
    News headline image
    VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
    Greater than 60% increase in laboratory space will strengthen R&D capabilities, facilitate acceleration toward clinical development, and increase ability to tap into Heidelberg’s world-class medical... 
    From VERAXA Biotech GmbH
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.